DepYmed and Monash Biomedicine Discovery Institute to Study the Role of a New Generation of PTP1B Inhibitors against a Novel Intracellular Checkpoint in Cancer
March 10, 2022 09:45 ET
|
DepYmed, Inc.
Research Agreement Capitalizes on Newly Published Monash Findings in Peer Reviewed Journal Cancer Discovery1 that PTP1B acts as an Intracellular Checkpoint and PTP1B Inhibition Represses Tumor Growth ...